The financing landscape for life sciences issuers has transformed over the last 5 years. In this three-part series, we will cover 1) the evolution of the typical life sciences IPO, 2) post-IPO financing dynamics and the importance of laying the foundation for successful capital raises, and 3) later ... >>>Read More
Post-SPAC Warrant Redemption Features (Part 3)
This is the third of a series of posts examining the redemption features of warrants in post-SPAC public companies. In the first post, we described typical redemption features in warrants. The second post discussed how issuers might economically analyze whether and when to redeem the warrants. ... >>>Read More
Post-SPAC Warrant Redemption Features (Part 2)
This is the second of a three-part series of posts examining the redemption features of warrants in post-SPAC public companies. In the first post, we described typical redemption features in warrants. Here we introduce economic frameworks for how issuers can approach the decision whether and when ... >>>Read More
Post-SPAC Warrant Redemption Features (Part 1)
This is the first of a three-part series of posts examining the redemption features of SPAC warrants: here, we describe the typical redemption features found in SPAC warrants. In subsequent posts we will examine (1) how to approach the decision whether and when to redeem warrants and (2) what ... >>>Read More